general/pan tumour

123456789101112131415161718
Across
  1. 6. Tumor staging criteria
  2. 7. Color of LIBTAYO
  3. 9. Dose of LIBTAYO given to patients
  4. 10. First line immune response
  5. 11. The immune response restored by LIBTAYO
  6. 12. Administration method of LIBTAYO
  7. 13. Immune function inhibited by LIBTAYO
  8. 15. LIBTAYO ________ enhances patient access to LIBTAYO
  9. 16. Approves drug indications
  10. 18. Generates fully human therapeutic antibodies, including LIBTAYO
Down
  1. 1. Information resource that contains efficacy, safety, and usage information for LIBTAYO
  2. 2. Criteria used to select patients for clinical trials
  3. 3. Expresses programmed death-receptor 1 (PD-1)
  4. 4. Statistical method often used in evaluating PFS
  5. 5. Objective response rate. Duration of Response. Complete response rate. Safety and tolerability.
  6. 8. LIBTAYO biologic
  7. 14. Number of approved FDA indications for LIBTAYO
  8. 15. Profile in which adverse reactions are reported
  9. 17. Method to confirm objective response rate (ORR)